www.actupny.org
Pharmaceutical Company Profits and Salaries
by Richard Laing, Department of International Health, School of Public Health,
Boston University, Presented @ Durban South Africa AIDS Conference 11 July 2000
| . . COMPANY |
REVENUE ( in millions ) |
Goods ( % revenue ) |
Market and Administration |
R & D ( % revenue ) |
Profits |
|
Merck Novartis BMS Pfizer Glaxo Wellcome AHP Abbott Warner-Lambert Smith Kline Eli Lilly Schering-Plough Pharmacia AMGEN Genenteck Biogen |
|
|
|
|
|
|
Charles A. Heimbold, Jr. |
Melvin R. Goodes |
|
|
|
|
|
Stock Options |
|
|
|
|
|
|
| *
includes salary, bonus and other compensation ** Includes salary listed above with stock option grants . |
Data from SEC filings and AFL-CIO websites |
|
U.S. Pharmaceutical Market
1998 - 1999Total pharmaceutical prescription sales: $107.1 billion:_ up 15.6% _(1998)
Promotional Spending:_$5.9 billion_(1998)
Leading Sellers:
Prilosec
Prozac
Augmentin
Cipro
Rocephin
Combivir
Viracept
Crixivan
$4.19 billion (99)
$2.57 billion (99)
$1.16 billion (99)
$921 million (99)
$517 million (99)
$465 million (99)
$448 million (99)
$223 million (99)
Sources: MM&M IMS America Business Watch May 1999 & Top 200 Drugs, Pharmacy Times April 2000
use back
button on browser to return
see also:
HIGH DRUG PRICES LINKED TO ADVERTISING, PROFITS, AND ENORMOUS EXECUTIVE SALARIES
see also OFF-SITE WEBSITES:
Compulsory Licensing and Parallel Importing
What do they mean? Improving access to essential drugs for people living with HIV/AIDS
International Council of AIDS Service Organizations (ICASO)
MEDECINS SANS FRONTIERES
HIV/AIDS medicines pricing report
Setting objectives: Is there a political will?
back to >>> Durban Conference Report
